Clinical response after 12 months of adalimumab treatment in patients with RA
| Switchers | ||||
|---|---|---|---|---|
| Drug failure | Adverse events | All switchers | Controls | |
| (n = 9) | (n = 15) | (n = 24) | (n = 25) | |
| No significant differences were seen between any group of switchers and the control group according to χ2 test for categorical parameters and Wilcoxon’s test for continuous variables. | ||||
| No (%) patients achieving: | ||||
| ACR 20% | 8 (89) | 10 (67) | 18 (75) | 19 (76) |
| ACR 50% | 5 (56) | 7 (47) | 12 (50) | 14 (56) |
| ACR 70% | 3 (33) | 5 (33) | 8 (33) | 9 (36) |
| EULAR | 7 (78) | 10 (67) | 17 (71) | 18 (72) |
| DAS28, mean (SD) | ||||
| Baseline | 5.4 (0.7) | 5.7 (0.8) | 5.6 (0.8) | 5.9 (0.9) |
| 12 Months | 3.3 (0.6) | 3.2 (0.6) | 3.2 (0.6) | 3.2 (0.7) |